NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis → America’s worst nightmare? (From Porter & Company) (Ad) Free VYGR Stock Alerts $8.48 +0.04 (+0.47%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$8.44▼$8.7950-Day Range$7.42▼$10.5452-Week Range$6.06▼$14.34Volume390,220 shsAverage Volume846,957 shsMarket Capitalization$461.23 millionP/E Ratio2.74Dividend YieldN/APrice Target$19.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Voyager Therapeutics alerts: Email Address Voyager Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside131.1% Upside$19.60 Price TargetShort InterestBearish7.74% of Shares Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment0.18Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.64) to ($1.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.97 out of 5 starsMedical Sector193rd out of 925 stocksBiological Products, Except Diagnostic Industry24th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Voyager Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.74% of the outstanding shares of Voyager Therapeutics have been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 21.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.97. Previous Next 1.8 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Voyager Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat FollowsOnly 39 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.64) to ($1.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 2.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 2.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 161.30.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceDoes this chart look familiar?Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above…Get all the information here. About Voyager Therapeutics Stock (NASDAQ:VYGR)Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More VYGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesMay 13 at 6:38 PM | sfgate.comVoyager Therapeutics: Q1 Earnings SnapshotMay 13 at 6:38 PM | msn.comVoyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02MMay 13 at 4:01 PM | globenewswire.comVoyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsMay 13 at 3:14 AM | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Short Interest Up 21.7% in AprilMay 11 at 1:44 AM | americanbankingnews.comVoyager Therapeutics (VYGR) Scheduled to Post Earnings on MondayMay 10 at 11:52 AM | msn.comVoyager 1 was in crisis in interstellar space. NASA wouldn’t give up.May 8, 2024 | msn.comThe Invincible - Official Voyager Update TrailerMay 8, 2024 | msn.com8 Coolest Starships in Star Trek: VoyagerMay 8, 2024 | finance.yahoo.comVoyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingMay 6, 2024 | finance.yahoo.comVoyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returnsMay 6, 2024 | globenewswire.comVoyager Therapeutics Announces First Quarter 2024 Conference Call and WebcastMay 6, 2024 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Moderate Buy" from BrokeragesApril 30, 2024 | msn.comScientist Warns That NASA’s Voyager Probes Are “Dodging Bullets Out There”April 29, 2024 | msn.com7 Star Trek: Voyager Alien Villains Worse Than Discoverys BreenApril 27, 2024 | msn.comSilent no more: NASA hears from Voyager 1, the most distant spacecraftApril 26, 2024 | yahoo.comInside NASA's 5-month fight to save the Voyager 1 mission in interstellar spaceApril 24, 2024 | msn.comNASA re-establishes communication with Voyager 1 interstellar spacecraft that went silent for monthsApril 24, 2024 | forbes.comNASA Celebrates As 1977’s Voyager 1 Phones Home At LastApril 24, 2024 | usatoday.comVoyager 1 had a problem. Here's how NASA fixed it from 15 billion miles away.April 24, 2024 | abcnews.go.comNASA's Voyager 1 sending readable data back to Earth for 1st time in 5 monthsApril 24, 2024 | msn.comAfter months of silence, Voyager 1 has returned NASA’s callsApril 23, 2024 | msn.comNASA’s Voyager 1 probe is finally making sense againApril 23, 2024 | yahoo.comVoyager-1 sends readable data again from deep spaceApril 23, 2024 | barrons.comNASA's Voyager 1 Phones Home After MonthsApril 23, 2024 | msn.comVoyager 1 sending data to Earth for 1st time in 5 monthsSee More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/13/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees162Year FoundedN/APrice Target and Rating Average Stock Price Target$19.60 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+131.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$3.09 Trailing P/E Ratio2.74 Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins52.93% Pretax Margin53.49% Return on Equity63.89% Return on Assets40.79% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.96 Sales & Book Value Annual Sales$250.01 million Price / Sales1.84 Cash Flow$3.04 per share Price / Cash Flow2.79 Book Value$5.37 per share Price / Book1.58Miscellaneous Outstanding Shares54,390,000Free Float51,832,000Market Cap$461.23 million OptionableOptionable Beta0.98 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 66)M.D., Ph.D., President, CEO & Director Comp: $825.41kDr. Krystof Bankiewicz M.D.Ph.D., FounderDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 65)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMr. Todd Carter Ph.D. (Age 54)Chief Scientific Officer Ms. Jacquelyn Fahey Sandell Esq.J.D., Chief Legal OfficerMs. Michelle Quinn SmithChief Human Resources OfficerMr. G. Andre Turenne (Age 50)Advisor Comp: $600.3kDr. Maria Lopez-Bresnahan M.B.A.M.D., Senior Vice President of Translational Medicine & Clinical DevelopmentMore ExecutivesKey CompetitorsC4 TherapeuticsNASDAQ:CCCCEditas MedicineNASDAQ:EDITTaysha Gene TherapiesNASDAQ:TSHAAdaptive BiotechnologiesNASDAQ:ADPTAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInsiders & InstitutionsO Shaughnessy Asset Management LLCSold 6,016 shares on 5/13/2024Ownership: 0.040%Ameritas Investment Partners Inc.Bought 1,300 shares on 5/13/2024Ownership: 0.007%Vanguard Group Inc.Bought 702,030 shares on 5/10/2024Ownership: 5.942%Acadian Asset Management LLCBought 42,029 shares on 5/10/2024Ownership: 0.845%ProShare Advisors LLCBought 10,876 shares on 5/8/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions VYGR Stock Analysis - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued 1-year target prices for Voyager Therapeutics' shares. Their VYGR share price targets range from $14.00 to $30.00. On average, they expect the company's share price to reach $19.60 in the next twelve months. This suggests a possible upside of 131.1% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2024? Voyager Therapeutics' stock was trading at $8.44 at the beginning of 2024. Since then, VYGR shares have increased by 0.5% and is now trading at $8.48. View the best growth stocks for 2024 here. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings results on Wednesday, February, 28th. The company reported $1.25 EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a trailing twelve-month return on equity of 63.89% and a net margin of 52.93%. What ETFs hold Voyager Therapeutics' stock? ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include Franklin Genomic Advancements ETF (HELX).iShares Neuroscience and Healthcare ETF (IBRN). What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.94%), Acadian Asset Management LLC (0.85%), ClariVest Asset Management LLC (0.18%), Allspring Global Investments Holdings LLC (0.18%), Hunter Perkins Capital Management LLC (0.12%) and Commonwealth Equity Services LLC (0.10%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYGR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.